Clinical trials: Treatment-resistant Schizophrenia
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Treatment-resistant Schizophrenia
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
This study includes two main components: the first screening phase and the second clinical intervention phase. During the screening phase, subjects with poor response to clozapine are carefully evaluated by chart-review and…
- Trial name
- M1106 (NCT01105481)
- Testing
- Amisulpride add-on
- Where
- 2 sites in Taiwan
- Volunteers
- 273 people
- Sponsor
- National Health Research Institutes, Taiwan
Schizophrenia and Related Disorders, Early Treatment-Resistance
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros.
- Trial name
- INTENSIFY SZ (NCT05958875)
- Testing
- Clozapine, Second-line Antipsychotics (treatment as usual)
- Where
- 13 sites in Austria, Germany and 3 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.
The effectiveness and efficacy of the combination of pharmacotherapy with the two new recovery-oriented programs, RECOVERYTRSGR for patients with treatment- resistant schizophrenia and RECOVERYTRSBDGR for patients with treatment…
- Trial name
- RAKGEORREC (NCT07047651)
- Testing
- Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine
- Where
- Greece
- Volunteers
- 84 people
- Sponsor
- Dr. Stavroula Rakitzi
Agranulocytosis, Neutropenia
Time Course of Clozapine-associated Agranulocytosis Over 19 Years
Clozapine is the most effective antipsychotic medication for treatment-resistant schizophrenia, but it carries a rare, potentially life-threatening risk of agranulocytosis (a severe drop in white blood cells), which is why…
- Conditions
- Agranulocytosis, Neutropenia, SCHIZOPHRENIA 1 (Disorder), Treatment-resistant Schizophrenia
- Trial name
- NCT07913529
- Where
- Israel
- Volunteers
- 2,020 people
- Sponsor
- Sheba Medical Center
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Hallucinations, Schizophrenia
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) This study…
- Conditions
- Hallucinations, Schizophrenia, Perceptual Disorders
- Trial name
- MULTIMODHAL (NCT01373866)
- Testing
- MagPro X100 repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Lille
Bipolar Affective Disorder, Schizoaffective Disorder
Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder
Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients. determine if after 12 months of treatment with clozapine, the BMI changes with clients who are councelled as usual regarding weight gain while on Clozapine.
- Trial name
- NCT00683709
- Testing
- Counselling as Usual, CBT
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Schizophrenia, Forensic Psychiatry
Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service.
- Conditions
- Schizophrenia, Forensic Psychiatry, Outcome Measure, Violence
- Trial name
- D-FOREST (NCT05074732)
- Where
- Ireland
- Volunteers
- 350 people
- Sponsor
- Health Service Executive, Ireland
Diabetes, Schizophrenia
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects…
- Conditions
- Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
- Trial name
- NCT00231894
- Testing
- Pioglitazone, Life style diet group
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizo Affective Disorder
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Trial name
- NCT03868839
- Testing
- Telmisartan Pill
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Xiaoduo Fan
Schizophrenia
D-serine in Schizophrenia
This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.
- Trial name
- DSRSZ (NCT03702933)
- Testing
- D-serine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Herzog Hospital
Schizophrenia Disorders, Schizo Affective Disorder
SEEG-Guided DBS for Schizophrenia
This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia.
- Trial name
- NCT07671261
- Testing
- SEEG implantation, Deep brain stimulation
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Schizophrenia
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
In this study, the investigators will investigate the impact and the related mechanism of metformin treatment on cognitive impairment of schizophrenia with a high risk of metabolic syndrome.
- Trial name
- NCT03271866
- Testing
- metformin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Central South University
Treatment Resistant Schizophrenia
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
The proposed study will be conducted to compare the efficacy of maintenance ECT (M-ECT) vs Clozapine in treatment resistant schizophrenia (TRS) in terms of change in psychopathology measures and cerebral hemodynamics.
- Trial name
- NCT03807882
- Testing
- Bilateral M-ECT, Clozapine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Treatment-resistant Schizophrenia, Deep Brain Stimulation
Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia
The purpose of this project is to improve the clinical response and personal recovery of patients with treatment-resistant schizophrenia (TRS).
- Trial name
- DBS-R (NCT05337904)
- Testing
- On-Stimulation, Off-Stimulation
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Clozapine Resistant Schizophrenia
Vitamin D for Schizophrenia
Background: Despite improvements in medications, treatment delivery and rehabilitation, schizophrenia outcomes remain suboptimal. There are a proportion of 30-40% treatment-resistant schizophrenia patients.
- Trial name
- NCT01759485
- Testing
- Vitamin D3
- Where
- Israel
- Volunteers
- 47 people
- Sponsor
- Geha Mental Health Center
Metabolic Syndrome
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes.
- Trial name
- ATOMICS (NCT00794963)
- Testing
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Schizophrenia, Prediabetic State
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and…
- Trial name
- HISTORI (NCT05193578)
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- Denmark
- Volunteers
- 154 people
- Sponsor
- Jan Frystyk
Schizophrenia
Efficacy of tACS for Treatment of Auditory Hallucinations in Refractory Schizophrenia
The aim of this study is to evaluate the feasibility and efficacy of transcranial alternating current stimulation (tACS) as an add-on treatment for auditory hallucinations in refractory schizophrenia.
- Trial name
- NCT05282329
- Testing
- Transcranial alternating Current Stimulation (tACS)-active
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Anding Hospital